Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wuyan Zhang

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Bioinformatics (Oxford, England)|March 9, 2007
Pooling mRNA in microarray experiments and its effect on powerWuyan Zhang, Alicia Carriquiry, Dan Nettleton, et al.
Genetics, Selection, Evolution : GSE|November 30, 2006
Comparison of methods for analysis of selective genotyping survival dataJoseph P McElroy, Wuyan Zhang, Kenneth J Koehler, et al.
RMD Open|September 30, 2022
Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritisJonathan Kay, Amy E Bock, Muhammad Rehman, et al.
Arthritis Research & Therapy|September 26, 2021
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trialRoy M Fleischmann, Daniel F Alvarez, Amy E Bock, et al.
RMD Open|April 22, 2021
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293Roy M Fleischmann, Daniel F Alvarez, Amy E Bock, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 15, 2014
Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's diseaseGerard J Marek, David A Katz, Andreas Meier, et al.
Rheumatology and Therapy|March 19, 2022
Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid ArthritisRoy M Fleischmann, Amy E Bock, Wuyan Zhang, et al.
Frontiers in Immunology|March 14, 2025
Antidrug antibodies to adalimumab do not associate with immunologically related adverse eventsSophie Tourdot, Maria-Dolores Vazquez-Abad, Donna S Cox, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|November 4, 2014
Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidismTadao Akizawa, Takashi Akiba, Hideki Hirakata, et al.
The Lancet. Rheumatology|January 22, 2024
Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group studyRoy M Fleischmann, Wassim Saikali, Sharad Lakhanpal, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Bioinformatics (Oxford, England)|March 9, 2007
Pooling mRNA in microarray experiments and its effect on powerWuyan Zhang, Alicia Carriquiry, Dan Nettleton, et al.
Genetics, Selection, Evolution : GSE|November 30, 2006
Comparison of methods for analysis of selective genotyping survival dataJoseph P McElroy, Wuyan Zhang, Kenneth J Koehler, et al.
RMD Open|September 30, 2022
Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritisJonathan Kay, Amy E Bock, Muhammad Rehman, et al.
Arthritis Research & Therapy|September 26, 2021
Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trialRoy M Fleischmann, Daniel F Alvarez, Amy E Bock, et al.
RMD Open|April 22, 2021
Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293Roy M Fleischmann, Daniel F Alvarez, Amy E Bock, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 15, 2014
Efficacy and safety evaluation of HSD-1 inhibitor ABT-384 in Alzheimer's diseaseGerard J Marek, David A Katz, Andreas Meier, et al.
Rheumatology and Therapy|March 19, 2022
Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid ArthritisRoy M Fleischmann, Amy E Bock, Wuyan Zhang, et al.
Frontiers in Immunology|March 14, 2025
Antidrug antibodies to adalimumab do not associate with immunologically related adverse eventsSophie Tourdot, Maria-Dolores Vazquez-Abad, Donna S Cox, et al.
Therapeutic Apheresis and Dialysis : Official Peer-Reviewed Journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy|November 4, 2014
Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidismTadao Akizawa, Takashi Akiba, Hideki Hirakata, et al.
The Lancet. Rheumatology|January 22, 2024
Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group studyRoy M Fleischmann, Wassim Saikali, Sharad Lakhanpal, et al.
Pageof 2